Background: Although uveal melanoma represents only 5% of all melanomas, it is the most common
primary intraocular malignancy of the adult eye. Approximately 50% of patients will develop metastases
which are resistant to medical interventions. There is a great need for improved therapy as the prognosis
is poor for advanced-stage disease. Our study was undertaken to investigate the presence of novel
therapeutic targets
Publications
Molecular Profiling of Uveal Melanoma Patients
– Caris Life Sciences